Amantadine Reduces Adverse Cardiovascular Outcomes in Patients With Parkinsonism or Parkinson Disease: A Global Propensity Score Matched Analysis
NMDA antagonism with amantadine in patients with primary or secondary parkinsonism is associated with a significantly reduced risk of all-cause mortality, AMI, cerebral infarction, heart failure, and arrhythmias.
Authors
- Bharat Rawlley (ORCID: https://orcid.org/0000-0003-4987-9661)
- Anderson Anuforo (ORCID: https://orcid.org/0000-0003-2523-6290)
- Dan Draytsel
- Jonathan P. Miller (ORCID: https://orcid.org/0000-0001-5441-1751)
- Subaina Khalid
- Mark Charlamb
- Kavipriya Kovai Palanivel
- Jacob Charlamb
Institutions
- SUNY Upstate Medical University (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Clinical Neuropharmacology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1097/wnf.0000000000000628
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78